Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVX-01 and Pembrolizumab in Advanced Melanoma
NCT05309421Phase 2Completed
- Sponsor
- Evaxion
- Start
- Sep 2022
- Primary completion
- Apr 2026
- Modality
- Targeted Liposomes, Split/Subunit Vaccines, Peptides
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of EVX-01 in melanoma, sponsored by Evaxion. Primary endpoint: Best Overall Response at 102 weeks. Started Sep 2022; status: completed.
02
Drugs
EVX-01
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05309421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309421.